TrialBritish journal of cancer2013

Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.

D Cella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.